Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 2 Recurrence 2 Leukemia, Myeloid, Acute 2 Uterine Cervical Neoplasms 1 Testicular Germ Cell Tumor 1 Stomach Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Myelodysplastic Syndromes 1 Melanoma 1 Liposarcoma 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Biliary Tract Neoplasms 1 Adrenocortical Carcinoma 1 Adenocarcinoma of Lung 1

Interventions

Trastuzumab 78 Capecitabine 59 Cyclophosphamide 54 Paclitaxel 52 Docetaxel 50 Letrozole 44 Fulvestrant 43 Lapatinib 34 Doxorubicin 31 Carboplatin 31 Vinorelbine 30 Bevacizumab 29 Anastrozole 28 pembrolizumab 26 exemestane 24 Tamoxifen 23 Gemcitabine 22 Radiotherapy 21 Albumin-Bound Paclitaxel 19 Taxes 17 Everolimus 17 Epirubicin 15 pertuzumab 13 Ado-Trastuzumab Emtansine 13 130-nm albumin-bound paclitaxel 13 palbociclib 12 Magnetic Resonance Spectroscopy 12 liposomal doxorubicin 11 atezolizumab 11 Filgrastim 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Breast Neoplasms × milademetan × Clear all

NCT05932667 2023-12-21

DEMETER

Institut Curie

Phase 2 Terminated

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡